Skip to main content

New Products: Asper Biotech's Mitochondrial Diseases Panels

Premium

Asper Biotech recently introduced a number of new test panels targeted to mitochondrial diseases. The panels rely on next-generation sequencing, Sanger sequencing, and array comparative genomic hybridization to examine alterations in mitochondrial genes, as well as in nuclear genes, associated with mitochondrial disorders.

Asper, based in Tartu, Estonia, is offering the panels via a genotyping service, which includes genotyping and an electronic copy of the results report; and as a diagnostic package service, which includes DNA extraction, detection of genetic variations, confirmation of disease associated variants by Sanger sequencing, biological and clinical interpretation of disease associated variants by medical doctors, and a final results report by registered mail.

Asper's array CGH-based panel detects deletions and duplications in dozens of select genes related to different mitochondrial diseases and disorders. It has a turnaround time of between four and six weeks. It is available as a genotyping service, priced at €940, and a diagnostic package service, which costs €1,200.

The company's NGS-based test covers the entire coding regions of 133 nuclear genes. Its genotyping service costs €1,300 and has a 13-week turnaround time, while its diagnostic package service costs €1,500 and has a 15-week turnaround time.

Asper is also offering an mtDNA genes sequencing test that relies on Sanger sequencing to analyze a panel of 25 genes. The genotyping service has a turnaround time of between four and six weeks and costs €850, while the diagnostic service package has the same turnaround time and costs €930.

The company will also provide Sanger sequencing of the mitochondrial genome. The genotyping service has a turnaround time of between four and six weeks and costs €990, and the diagnostic services package costs €1,100, with the same turnaround time.

According to Asper, individuals who order all four tests can receive a 10 percent discount on the total cost. More information about the new mitochondrial testing panels is available here.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.